Percheron Therapeutics (ASX:PER) is a clinical-stage Australian immuno-oncology company which is progressing to Phase 2 in 2026. The magic of supressing VISTA HMBD-002, is a monoclonal antibody targeting VISTA, a next-generation immune checkpoint. VISTA can suppress T-cell responses to cancer treatments and the idea is that by ‘drugging VISTA’, cancer treatments can be more efficacious. […]